The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
BUSINESS
Daiichi Sankyo/Amgen’s Avastin Biosimilar Now Available
Daiichi Sankyo on December 19 launched its biosimilar version of Avastin (bevacizumab), which was developed by US partner Amgen, in Japan for the treatment of unresectable advanced or recurrent colorectal cancer. This is the second follow-on for the stalwart cancer…
To read the full story
Related Article
- Pfizer Rolls Out Japan’s 1st Avastin Biosimilar
December 10, 2019
- Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing
November 27, 2019
- Japan Clears First Biosimilars for Nesp and Forteo, Second Rituxan, Avastin Follow-Ons Too
September 24, 2019
- Japan Approves 1st Avastin Biosimilar
June 19, 2019
BUSINESS
- Takeda Looks to Derive 70%-Plus of Japan Sales from 5 Focus Areas by FY2025, Revamp HR Systems
July 13, 2020
- Eisai Joins Forces with Four Universities on R&D of Lupus Drug
July 13, 2020
- Bayer Revving Up Cell Therapy Drive with First Focus on Parkinson’s, Japan Biz Also Eyed: R&D Chief
July 10, 2020
- Yoshiaki Aono to Be Promoted to Chairman and President of Nippon BI in September
July 10, 2020
- Maruho’s Nemolizumab Hits Primary Goal in Japanese PIII for Itching in Atopic Dermatitis
July 10, 2020
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…